Biochemical evaluations in skeletal muscles of primates with MPTP Parkinson-like syndrome.
The toxic effects of the neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) in primates can be exploited for investigating the physiopathology of Parkinson's disease which may also cause functional alterations of skeletal muscles, whose biochemical modifications have been studied very little. Some enzyme activities related to energy transduction in skeletal muscles were evaluated (gastrocnemius, soleus and biceps) from MPTP-treated monkeys. Systemically administered MPTP altered the enzyme activities related to: (i) the anaerobic glycolytic pathway (decrease in hexokinase and phosphofructokinase activities; increase in lactate dehydrogenase activity); (ii) the tricarboxylic acid cycle (decrease in malate dehydrogenase activity); (iii) the electron transfer chain (decrease in cytochrome oxidase activity related to complex IV). No alteration in mitochondrial Complex I was observed. Treatment with an ergot alkaloid derivative (dihydroergocryptine) modified some alterations in the muscle enzyme activities and reduced the rigidity and some autonomic dysfunction.
Pastoris
O
O
Institute of Pharmacology, Faculty of Science, University of Pavia, Italy.
Dossena
M
M
Foppa
P
P
Catapano
M
M
Ferrari
R
R
Dagani
F
F
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000494:pharmacology; D000818:Animals; D004195:Disease Models, Animal; D003576:Electron Transport Complex IV / Q000187:drug effects; D004798:Enzymes / Q000187:drug effects*; D007275:Injections, Intravenous; D008253:Macaca mulatta; D008297:Male; D018482:Muscle, Skeletal / Q000187:drug effects* / Q000201:enzymology; D010302:Parkinson Disease, Secondary / Q000139:chemically induced* / Q000201:enzymology; D013997:Time Factors
D004798:Enzymes; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D003576:Electron Transport Complex IV